Because DPP4 inhibitors are typically used as second or third-line agents for glycemic control in type two diabetes, a small sample size of diabetic patients on DPP4 inhibitors who had advanced-stage prostate were identified. This evidence concerns the gene DPP4 and urogenital neoplasm.